Protalix BioTherapeutics (PLX) Misses Q3 EPS by 9c; Reports Cash and Cash Equivalents of $48.7M
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.67 +1.91%
EPS Growth %: -133.3%
Financial Fact:
REVENUES: 4.67M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -133.3%
Financial Fact:
REVENUES: 4.67M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q3 EPS of ($0.09), $0.09 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $12.05 million versus the consensus estimate of $6.9 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- BlackRock’s Rosenberg says inflation data key after jobs beat
- JPMorgan Starts Bytes Technology Group PLC (BYIT:LN) at Underweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
